These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28190710)

  • 1. Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma.
    Taussig MD; Irene Koran ME; Mouli SK; Ahmad A; Geevarghese S; Baker JC; Lipnik AJ; Banovac F; Brown DB
    HPB (Oxford); 2017 May; 19(5):458-464. PubMed ID: 28190710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil/Lymphocyte Ratio Predicts Increased Risk of Immediate Progressive Disease following Chemoembolization of Hepatocellular Carcinoma.
    Cruz JC; Watchmaker JM; Albin MM; Wang L; Wu G; Baker JC; Fritsche MR; Alexopoulos SP; Matsuoka L; Fleming JW; Su J; Borgmann AJ; Banovac F; Brown DB
    J Vasc Interv Radiol; 2019 Dec; 30(12):1887-1892. PubMed ID: 31669086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    Huang ZL; Luo J; Chen MS; Li JQ; Shi M
    J Vasc Interv Radiol; 2011 May; 22(5):702-9. PubMed ID: 21514523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization.
    Liu C; Li L; Lu WS; Du H; Yan LN; Yang JY; Wen TF; Zeng GJ; Jiang L; Yang J
    Sci Rep; 2017 Oct; 7(1):13873. PubMed ID: 29066730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
    Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
    J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Pang Q; Zhou L; Qu K; Cui RX; Jin H; Liu HC
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):60-70. PubMed ID: 29189392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation.
    Chen TM; Lin CC; Huang PT; Wen CF
    J Gastroenterol Hepatol; 2012 Mar; 27(3):553-61. PubMed ID: 21913982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Xu X; Chen W; Zhang L; Miao R; Zhou Y; Wan Y; Dong Y; Liu C
    Chin Med J (Engl); 2014; 127(24):4204-9. PubMed ID: 25533822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis.
    Yang HJ; Guo Z; Yang YT; Jiang JH; Qi YP; Li JJ; Li LQ; Xiang BD
    World J Gastroenterol; 2016 Jun; 22(21):5088-95. PubMed ID: 27275101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.
    Kim JK; Kim HD; Jun MJ; Yun SC; Shim JH; Lee HC; Lee D; An J; Lim YS; Chung YH; Lee YS; Kim KM
    Dig Dis Sci; 2017 Oct; 62(10):2923-2931. PubMed ID: 28815349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
    Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.
    Xue TC; Jia QA; Ge NL; Chen Y; Zhang BH; Ye SL
    Tumour Biol; 2015 Nov; 36(11):8797-803. PubMed ID: 26058874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis.
    Arai K; Fukumoto T; Kido M; Tanaka M; Kuramitsu K; Kinoshita H; Komatsu S; Tsugawa D; Terai S; Matsumoto T; Goto T; Asari S; Toyama H; Ajiki T; Ku Y
    Surg Today; 2017 Mar; 47(3):385-392. PubMed ID: 27465474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI).
    Ji F; Liang Y; Fu SJ; Guo ZY; Shu M; Shen SL; Li SQ; Peng BG; Liang LJ; Hua YP
    BMC Cancer; 2016 Feb; 16():137. PubMed ID: 26907597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to select suitable hepatocellular carcinoma for liver transplantation by preoperative neutrophil-lymphocyte ratio.
    Xiao GQ; Yan L; Yang J
    Hepatogastroenterology; 2014 Oct; 61(135):2077-83. PubMed ID: 25713913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis.
    Li SH; Wang QX; Yang ZY; Jiang W; Li C; Sun P; Wei W; Shi M; Guo RP
    World J Gastroenterol; 2017 May; 23(17):3122-3132. PubMed ID: 28533669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.